Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Friday, December 9, 2022 at 11:30-1:30 PM CST / 12:30-2:30 PM EST

Join CLL Society and PeerView Institute to hear discussions about how integrating targeted therapeutics, including second-generation BTK inhibitors and emerging cellular therapies, can improve care across the clinical spectrum of CLL during this ASH 2022 Symposium, taking place both live and virtually.

This symposium will convene a panel of leading chronic lymphocytic leukemia experts who will blend case-based discussions with short lectures to illustrate how integrating targeted therapeutics can improve care across the CLL spectrum. Hear about important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies; therapeutic sequencing in progressive disease settings; safety management and distinctions among agent classes; the use of MRD assessment as a treatment tool; and next-generation and novel combinatorial strategies. Featuring experts such as Drs. John G. Gribben, Barbara Eichhorst, Nitin Jain, and Anthony R. Mato, as well as 22-year CLL survivor Terry Evans.